Development of Co-Amorphous Systems for Inhalation Therapy—Part 2: In Silico Guided Co-Amorphous Rifampicin–Moxifloxacin and –Ethambutol Formulations
Sign Up to like & getrecommendations! Published in 2025 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics17101339
Abstract: Background/Objectives: Tuberculosis (TB) remains a global health challenge due to long treatment durations, poor adherence, and growing drug resistance. Inhalable co-amorphous systems (COAMS) offer a promising strategy for targeted pulmonary delivery of fixed-dose combinations, improving… read more here.
Keywords: mox; amorphous systems; rif; rif mox ... See more keywords